Belgium (BE)

Spin-Orbit Photonics in 3D Rotated Anisotropic Materials (2022) Jisha CP, Beeckman J, Nolte S, Alberucci A Conference contribution Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: (Annals of Oncology (2021) 32(3) (309–322), (S0923753420431692), (10.1016/j.annonc.2020.11.014)) (2022) Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, et al. Journal article, Erratum EAPC Core Curriculum for Preventive Cardiology (2022) Wilhelm M, Abreu A, Adami PE, Ambrosetti M, Antonopoulou M, Biffi A, Cavarretta E, et al. Journal article Preventing heart failure: A position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology (2022) Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Bohm M, Butler J, et al. Journal article Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. (2022) Cavagna L, Meloni F, Meyer A, Sambataro G, Belliato M, De Langhe E, Cavazzana I, et al. Journal article Keratose sponges in ancient carbonates – A problem of interpretation (2022) Neuweiler F, Kershaw S, Boulvain F, Matysik M, Sendino C, McMenamin M, Munnecke A Journal article Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study (2022) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, et al. Journal article A Full D-band Multi-Gbit RF-DAC in 90 nm SiGe BiCMOS based on Passive Vector Aggregation (2022) Maiwald T, Visweswaran A, Aufinger K, Weigel R Conference contribution Experimental Evaluation of a Stiffness-Fault-Tolerant Control Strategy on an Elastic Actuator for Wearable Robotics (2022) Velasco Guillen RJ, Grosu V, Vanderborght B, Font-Llagunes JM, Beckerle P Conference contribution Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial (2022) Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, et al. Journal article